Logo for Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Investor Relations Material

Latest events

Logo for Vertex Pharmaceuticals Inc

Q1 2025

Vertex Pharmaceuticals
Logo for Vertex Pharmaceuticals

Q1 2025

5 May, 2025
Logo for Vertex Pharmaceuticals

Q4 2024

10 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies

Latest reports from Vertex Pharmaceuticals Inc

Access all reports
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. Its products include KALYDECO (ivacaftor), ORKAMBI (lumacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), VX-445, and VX-659, as well as other product candidates at various stages of research, development, and commercialization. The company has collaboration agreements with CRISPR Therapeutics AG; Moderna, Inc.; CRISPR Therapeutics AG; Editas Medicine, Inc.; Frontline BioVentures; Merck & Co., Inc.; Cystic Fibrosis Foundation Therapeutics, Incorporated; Bristol-Myers Squibb Company; Altimmune, Inc.; and Tesaro, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.